Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. Our mission is to extend and improve the quality of life for cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects normally associated with cancer treatment.
RX-3117 is a novel, oral, small molecule nucleoside prodrug which is activated (phosphorylated) by UCK2, a kinase that is predominantly expressed in cancer cells. Once activated within the cancer cell, RX-3117 is incorporated into the DNA or RNA inducing apoptotic death of tumor cells.
RX-5902 modulates the activity of the β-catenin/Wnt pathway which is a key pathway involved in cancer cell growth and proliferation, oncogene expression and -activation of the immune response to cancer. RX-5902 modulates the pathway through inhibition of phosphorylated p68 which is over-expressed in tumor cells.
RX-0301 is an antisense oligonucleotide that inhibits translation of the mRNA responsible for coding Akt-1. Akt-1 is a protein that is associated with cancer cell growth and proliferation and the development of resistance to certain anticancer agents. Akt-1 is over-expressed in multiple forms of cancer including hepatic, renal, breast, colorectal, gastric, pancreatic, prostate and melanoma.
Aug 7, 2019 6:30am EDT
May 28, 2019 4:10pm EDT
May 13, 2019 8:00am EDT
Apr 16, 2019 8:00am EDT
Stay informed and receive company updates straight to your inbox.